125 related articles for article (PubMed ID: 33278749)
1. Toll-like receptor 4 signaling pathway is correlated with pathophysiological characteristics of AML patients and its inhibition using TAK-242 suppresses AML cell proliferation.
Baakhlagh S; Kashani B; Zandi Z; Bashash D; Moradkhani M; Nasrollahzadeh A; Yaghmaei M; Mousavi SA; Ghaffari SH
Int Immunopharmacol; 2021 Jan; 90():107202. PubMed ID: 33278749
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitor of TLR4 inhibits ovarian cancer cell proliferation: new insight into the anticancer effect of TAK-242 (Resatorvid).
Kashani B; Zandi Z; Bashash D; Zaghal A; Momeny M; Poursani EM; Pourbagheri-Sigaroodi A; Mousavi SA; Ghaffari SH
Cancer Chemother Pharmacol; 2020 Jan; 85(1):47-59. PubMed ID: 31786654
[TBL] [Abstract][Full Text] [Related]
3. The anticancer effect of the TLR4 inhibition using TAK-242 (resatorvid) either as a single agent or in combination with chemotherapy: A novel therapeutic potential for breast cancer.
Zandi Z; Kashani B; Bashash D; Poursani EM; Mousavi SA; Chahardoli B; Ghaffari SH
J Cell Biochem; 2020 Feb; 121(2):1623-1634. PubMed ID: 31535397
[TBL] [Abstract][Full Text] [Related]
4. Synergistic killing effects of homoharringtonine and arsenic trioxide on acute myeloid leukemia stem cells and the underlying mechanisms.
Tan M; Zhang Q; Yuan X; Chen Y; Wu Y
J Exp Clin Cancer Res; 2019 Jul; 38(1):308. PubMed ID: 31307525
[TBL] [Abstract][Full Text] [Related]
5. TAK-242 selectively suppresses Toll-like receptor 4-signaling mediated by the intracellular domain.
Kawamoto T; Ii M; Kitazaki T; Iizawa Y; Kimura H
Eur J Pharmacol; 2008 Apr; 584(1):40-8. PubMed ID: 18299127
[TBL] [Abstract][Full Text] [Related]
6. The expression of Toll-like receptors in patients with acute myeloid leukemia treated with induction chemotherapy.
Rybka J; Butrym A; Wróbel T; Jaźwiec B; Stefanko E; Dobrzyńska O; Poręba R; Kuliczkowski K
Leuk Res; 2015 Mar; 39(3):318-22. PubMed ID: 25624047
[TBL] [Abstract][Full Text] [Related]
7. TLR4 blockade using TAK-242 suppresses ovarian and breast cancer cells invasion through the inhibition of extracellular matrix degradation and epithelial-mesenchymal transition.
Zandi Z; Kashani B; Poursani EM; Bashash D; Kabuli M; Momeny M; Mousavi-Pak SH; Sheikhsaran F; Alimoghaddam K; Mousavi SA; Ghaffari SH
Eur J Pharmacol; 2019 Jun; 853():256-263. PubMed ID: 30930249
[TBL] [Abstract][Full Text] [Related]
8. The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells.
Spinello I; Saulle E; Quaranta MT; Pasquini L; Pelosi E; Castelli G; Ottone T; Voso MT; Testa U; Labbaye C
Haematologica; 2019 May; 104(5):973-985. PubMed ID: 30467201
[TBL] [Abstract][Full Text] [Related]
9. Blockade of TLR4 using TAK-242 (resatorvid) enhances anti-cancer effects of chemotherapeutic agents: a novel synergistic approach for breast and ovarian cancers.
Kashani B; Zandi Z; Karimzadeh MR; Bashash D; Nasrollahzadeh A; Ghaffari SH
Immunol Res; 2019 Dec; 67(6):505-516. PubMed ID: 32026322
[TBL] [Abstract][Full Text] [Related]
10. Blockade of JAK2/STAT3 intensifies the anti-tumor activity of arsenic trioxide in acute myeloid leukemia cells: Novel synergistic mechanism via the mediation of reactive oxygen species.
Mesbahi Y; Zekri A; Ghaffari SH; Tabatabaie PS; Ahmadian S; Ghavamzadeh A
Eur J Pharmacol; 2018 Sep; 834():65-76. PubMed ID: 30012499
[TBL] [Abstract][Full Text] [Related]
11. Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.
Barghout SH; Patel PS; Wang X; Xu GW; Kavanagh S; Halgas O; Zarabi SF; Gronda M; Hurren R; Jeyaraju DV; MacLean N; Brennan S; Hyer ML; Berger A; Traore T; Milhollen M; Smith AC; Minden MD; Pai EF; Hakem R; Schimmer AD
Leukemia; 2019 Jan; 33(1):37-51. PubMed ID: 29884901
[TBL] [Abstract][Full Text] [Related]
12. Inhibitory Effects of Arsenic Trioxide and Thalidomide on Angiogenesis and Vascular Endothelial Growth Factor Expression in Leukemia Cells.
Mohammadi Kian M; Mohammadi S; Tavallaei M; Chahardouli B; Rostami S; Zahedpanah M; Ghavamzadeh A; Nikbakht M
Asian Pac J Cancer Prev; 2018 Apr; 19(4):1127-1134. PubMed ID: 29699374
[TBL] [Abstract][Full Text] [Related]
13. Homoharringtonine potentiates the antileukemic activity of arsenic trioxide against acute myeloid leukemia cells.
Chen P; Zhan W; Wang B; You P; Jin Q; Hou D; Wang X; You R; Zou H; Chen Y; Huang H
Exp Cell Res; 2019 Mar; 376(2):114-123. PubMed ID: 30763586
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-204 Potentiates the Sensitivity of Acute Myeloid Leukemia Cells to Arsenic Trioxide.
Wang Z; Fang Z; Lu R; Zhao H; Gong T; Liu D; Hong L; Ma J; Zhang M
Oncol Res; 2019 Sep; 27(9):1035-1042. PubMed ID: 30982490
[TBL] [Abstract][Full Text] [Related]
15. The expression of Toll-like receptors and development of severe sepsis in patients with acute myeloid leukemias after induction chemotherapy.
Rybka J; Butrym A; Wróbel T; Jaźwiec B; Stefanko E; Dobrzyńska O; Poręba R; Kuliczkowski K
Med Oncol; 2014 Dec; 31(12):319. PubMed ID: 25412934
[TBL] [Abstract][Full Text] [Related]
16. TAK-242 (resatorvid), a small-molecule inhibitor of Toll-like receptor (TLR) 4 signaling, binds selectively to TLR4 and interferes with interactions between TLR4 and its adaptor molecules.
Matsunaga N; Tsuchimori N; Matsumoto T; Ii M
Mol Pharmacol; 2011 Jan; 79(1):34-41. PubMed ID: 20881006
[TBL] [Abstract][Full Text] [Related]
17. TBC1D16 predicts chemosensitivity and prognosis in adult acute myeloid leukemia (AML) patients.
Liu H; Chen P; Yang YL; Zhu KW; Wang T; Tang L; Liu YL; Cao S; Zhou G; Zeng H; Zhao XL; Zhang W; Chen XP
Eur J Pharmacol; 2021 Mar; 895():173894. PubMed ID: 33476656
[TBL] [Abstract][Full Text] [Related]
18. TLR4/NF-κB axis induces fludarabine resistance by suppressing TXNIP expression in acute myeloid leukemia cells.
Huy H; Kim TD; Kim WS; Kim DO; Byun JE; Kim MJ; Park YJ; Yoon SR; Noh JY; Lee J; Lee KH; Choi I; Jung H
Biochem Biophys Res Commun; 2018 Nov; 506(1):33-40. PubMed ID: 30336978
[TBL] [Abstract][Full Text] [Related]
19. Toll-like Receptor 4, Osteoblasts and Leukemogenesis; the Lesson from Acute Myeloid Leukemia.
Bruserud Ø; Reikvam H; Brenner AK
Molecules; 2022 Jan; 27(3):. PubMed ID: 35163998
[TBL] [Abstract][Full Text] [Related]
20. p70S6 kinase is a target of the novel proteasome inhibitor 3,3'-diamino-4'-methoxyflavone during apoptosis in human myeloid tumor cells.
Piedfer M; Bouchet S; Tang R; Billard C; Dauzonne D; Bauvois B
Biochim Biophys Acta; 2013 Jun; 1833(6):1316-28. PubMed ID: 23481040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
